1. Coronaviruses and the COVID-19 pandemic {#sec1}
==========================================

Coronaviruses (CoVs) are important human and animal pathogens that have the ability to emerge and cross the species barrier, causing novel and occasionally fatal diseases \[[@bib1],[@bib2]\]. They belong to the subfamily *Coronavirinae* of the *Coronaviridae* family in the order *Nidovirales* \[[@bib3]\]. According to the International Committee on the Taxonomy of Viruses (ICTV), coronaviruses are classified into four genera including, *alphacoronavirus*, *betacoronavirus* (contains 4 lineages A, B, C and D), *gammacoronavirus* and *deltacoronavirus* \[[@bib4]\]. They are large enveloped viruses with a large single-stranded RNA, 5′-capped, non-segmented genome with positive polarity ranging from 26 to 32 kb in size \[[@bib5]\]. While CoVs from all genera infect a large number of mammals and birds, bats are proposed to be their natural reservoir \[[@bib6],[@bib7]\]. In humans, on the other hand, only alpha and beta CoVs have been associated with diseases ranging from mild common cold to fatal severe respiratory infections. Two human alpha CoVs (hCoV-229E and hCoV-NL63) and two beta CoVs (hCoV-OC43 and hCoV-HKU1) are associated with common cold \[[@bib8], [@bib9], [@bib10], [@bib11]\]. In 2002 and 2012, two novel highly pathogenic beta CoVs known as the severe acute respiratory syndrome-CoV (SARS-CoV) and the Middle East respiratory syndrome-CoV (MERS-CoV) emerged in China and Saudi Arabia, respectively \[[@bib12], [@bib13], [@bib14], [@bib15]\]. These two viruses have spread widely and were associated with severe respiratory diseases with mild to severe and fatal outcomes. More recently, a novel human CoV known as severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) emerged in December 2019 in Wuhan, the capital city of Hubei province in China as the third known highly pathogenic human beta CoV \[[@bib16]\].

Since its emergence, SARS-CoV-2, which causes the Coronavirus Disease (COVID-19), has rapidly spread to more than 214 countries around the world, causing a large-scale global pandemic. Until April 10^th^, more than 1.6 million COVID-19 confirmed cases have been reported globally, including more than 100,000 deaths. There are currently no vaccines or specific antiviral drugs for SARS-CoV-2 \[[@bib17]\]. The rapid global spread of this virus and the worrisome associated mortality rate encouraged the medical community and policy makers to expediate the process of exploring all available and potential interventions to control and mitigate this outbreak \[[@bib18]\]. Several interventional treatment options for COVID-19 have been suggested with unclear efficacy and safety considerations \[[@bib19]\]. Recent publications have suggested using chloroquine (CQ), a broadly used antimalarial drug, and its derivative hydroxychloroquine (HCQ) as a treatment for COVID-19 patients \[[@bib20], [@bib21], [@bib22]\]. In this review, we explore the antiviral activities of CQ and HCQ against CoVs and non-CoVs in the majority of previously published *in vitro*, *in vivo* and clinical trial studies with an aim to find evidence that supports their use in COVID-19 patients.

2. Possible mechanisms of CQ and HCQ antiviral activities {#sec2}
=========================================================

Both CQ and HCQ, known antimalarial and antirheumatic drugs, have closely related chemical structures \[[@bib22]\]. However, their mechanisms of action are still not fully elucidated. Several studies have revealed that both drugs have antiviral activity *in vitro* through different mechanisms \[[@bib23], [@bib24], [@bib25]\]. In particular, CQ has been shown to interfere with different stages of the viral life cycle as shown in [Fig. 1](#fig1){ref-type="fig"} \[[@bib26], [@bib27], [@bib28], [@bib29]\]. Different studies have reported the ability of CQ to inhibit viral entry \[[@bib30], [@bib31], [@bib32]\], uncoating \[[@bib33]\], assembly and budding \[[@bib34],[@bib35]\]. One of the suggested mechanisms by which CQ can affect the entry step of viruses is by inhibiting quinone reductase 2 \[[@bib36]\], which is required for the biosynthesis of sialic acid \[[@bib37]\]. Sialic acid was found to be involved in virus attachment and entry into host cells by several viruses including hCoV-OC43 and MERS-CoV \[[@bib38],[@bib39]\]. Moreover, CQ was shown to potently inhibit entry of SARS-CoV into cells by interfering with the glycosylation of its cellular receptor angiotensin converting enzyme 2 receptor (ACE2). SARS-CoV-2 also uses ACE2 as a receptor for cell entry, suggesting a possible similar effect of CQ on SARS-CoV-2 at this step of virus replication \[[@bib40]\]. CQ can also affect early stage of virus replication by inhibiting virus-endosome fusion, likely via increasing endosomal pH \[[@bib41]\]. CoVs such as SARS-CoV were shown to be able to enter target cells via pH-dependent mechanism in which the acidic pH of the lysosome triggers fusion of the viral and endosomal membranes resulting in viral particle uncoating and subsequent release of viral nucleic acid into the cytoplasm \[[@bib42]\]. CQ can also impair posttranslational modifications of viral proteins through interfering with proteolytic processes \[[@bib43]\] and inhibition of glycosylation via specific interactions with sugar-modifying enzymes or glycosyltransferases \[[@bib28]\]. CQ can also hamper lysosomal protein degradation and lysosomal fusion with autophagosomes \[[@bib44], [@bib45], [@bib46]\]. Moreover, it has been suggested that CQ has the ability to affect the cytotoxic mechanisms and works as anti-autophagy agent *in vitro* \[[@bib47]\]. CQ works as anti-inflammatory agent through reducing tumor necrosis factor (TNFα) release and suppressing TNF receptors on monocytes \[[@bib26],[@bib28]\].Fig. 1Cellular and molecular possible sites of action of CQ ± HCQ as antiviral agents. (X) Represents the site of inhibition by CQ ± HCQ. (1) CQ and HCQ inhibit virus binding to its cell surface receptor, (2) CQ inhibits sialic acid biosynthesis through suppressing quinone reductase 2 activity which affect ACE2 receptor activity, (3) CQ and HCQ inhibit virus pH-dependent endocytosis through increasing pH, (4) CQ interferes with virus uncoating, (5) CQ interferes with assembly/budding leading to accumulation of viral vesicles within trans-Golgi network, (6) CQ interferes with lysosomal protein degradation and lysosomal fusion with autophagosomes. HCQ can interfere with lysosomal activity and prevent major histocompatibility complex (MHC) class II expression, (7) CQ interferes with TNF release and binding from macrophages and/to monocytes, (8) CQ inhibits phosphorylation of P38 MAPK and caspase in Th1 cells which in turn inhibits pro-inflammatory cytokines production and virus replication, (9) HCQ blocking of MHC expression prevents T cell activation, expression of CD145 and cytokines release, (10) HCQ impairs TLR signaling through increasing endosomal pH and interfering with TLR7 and TLR9 binding to their DNA/RNA ligands thereby inhibiting transcription of pro-inflammatory genes, (11) HCQ inhibits the binding of DNA to the cGAS and therefore reduce cytokines transcription and production. ACE2: Angiotensin converting enzyme 2; MHC: Major histocompatibility complex; TLR: Toll-like receptors; cGAS: Cyclic GMP-AMP synthase; MAPK: Mitogen-activated protein kinase. This figure was created with [BioRender.com](http://BioRender.com){#intref0035}.Fig. 1

On the other hand, HCQ has similar effects to CQ in interfering with the glycosylation of ACE2, blocking virus/cell fusion and inhibiting lysosomal activity by increasing pH \[[@bib22]\]. HCQ can also impede major histocompatibility complex (MCH) class II expression which inhibits T cell activation, expression of CD145 and cytokines release \[[@bib48], [@bib49], [@bib50]\]. Furthermore, HCQ has been shown to impair Toll-like receptors (TLRs) signaling through increasing endosomal pH and interfering with TLR7 and TLR9 binding to their DNA/RNA ligands thereby inhibiting transcription of pro-inflammatory genes \[[@bib51], [@bib52], [@bib53]\]. The aforementioned immunomodulatory properties of CQ and HCQ have raised the interest in using these drugs in COVID-19 patients at risk of cytokines release syndrome (CRS) \[[@bib22]\].

3. CQ and HCQ pharmacokinetics {#sec3}
==============================

The fact that both CQ and HCQ are considered for the management of COVID-19 patients clearly highlights the need to better understand their pharmacokinetics (PK) parameters. However, a full understanding of these parameters has been challenging despite the numerous reported studies. Generally, PK parameters for CQ and HCQ are comparable ([Table 1](#tbl1){ref-type="table"} ) \[[@bib54],[@bib55]\]. Following oral administration of CQ and HCQ, their bioavailability can reach up to 80% with plasma peak time around 2--4 h \[[@bib56], [@bib57], [@bib58]\]. Thus, parenteral administration, if available, might be a better route especially that oral administration has shown huge interpatient variability \[[@bib56],[@bib59],[@bib60]\]. The long half-life of both CQ and HCQ which could range from 30 to 60 days is likely attributed to their large volume of distribution (200--800 L/kg) and extensive tissue uptake \[[@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68]\]. CQ and HCQ are metabolized via CYP-450 enzymes to other active compounds, which are responsible for the extended pharmacological actions and increased toxicity \[[@bib61],[@bib69]\]. Up to 60% of CQ and HCQ is primarily excreted renally as unchanged or metabolized forms, and the remaining (40%) is usually cleared through the liver, feces and skin or stored in other lean body tissues \[[@bib54],[@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib74]\]. It\'s important to note that CQ and HCQ have a chiral center, which produces two enantiomers R(−) or S(+) forms or isomers \[[@bib75]\], in which little is known about the differences in their pharmacological activity and their corresponding metabolites. Most clinically used CQ and HCQ exist as a racemic mixture (50:50) of both isomers which complicates the understanding of their PK and associated toxicity as they could behave differently inside the body \[[@bib57],[@bib75], [@bib76], [@bib77]\].Table 1CQ and HCQ pharmacokinetic parameters.Table 1Pharmacokinetic parametersCQHCQ**Bioavailability**89 ± 16%74 ± 13%**Half-life**30--60 days30--52 days**Peak plasma time**2--4 h**Metabolism**Liver CYP-450**Excretion**Kidney and liver (40--60%) unchanged or metabolized

4. CQ and HCQ adverse effects and related toxicities {#sec4}
====================================================

The most common CQ and HCQ adverse effects are gastrointestinal symptoms such as nausea, vomiting and abdominal discomfort \[[@bib78]\], and uncommonly worrisome fulminant hepatic failure \[[@bib79]\], toxic epidermal necrolysis (TEN) \[[@bib80]\] and cardiotoxicity that could manifest with QT abnormality \[[@bib81], [@bib82], [@bib83]\]. Nevertheless, over the years CQ and HCQ have maintained a good safety profile when used in several chronic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Despite some animal experiments suggesting that HCQ is probably less toxic than CQ, there is a lack of high quality evidence from clinical trials supporting this claim \[[@bib74],[@bib84], [@bib85], [@bib86], [@bib87]\]. These toxicities could be related to the very long half-life and the large volume of distribution of both drugs. One of the significant toxic effects of CQ and HCQ is the possible ocular pigmentation due to their binding to melanin, which could lead to damage in different parts of the eye including the cornea, ciliary body and retina \[[@bib88]\]. Notably, the incidence of such ocular toxicity is usually rare. For instance, it was shown that only 0.5% out of \~400 patients treated with HCQ (≤6.5 mg/kg/day) for 6 years due to RA or SLE had developed ocular related complications \[[@bib89]\]. Most studies have shown that such complications might only occur with long term treatment of chronic diseases which extends for more than 5 years with doses above or equal to 6.5 mg/kg/day \[[@bib90],[@bib91]\]. However, ocular toxicity and changes could still occur with shorter treatments. Other complications such as development of proximal myopathy associated with respiratory failure have also been reported in patients treated with either CQ or HCQ \[[@bib92], [@bib93], [@bib94], [@bib95]\]. Nonetheless, most of these complications were seen in elderly patients with an average age of 70 years suffering from chronic RA or autoimmune diseases. Both CQ and HCQ were also shown to be associated with rare but life-threatening cardiomyopathy \[[@bib96], [@bib97], [@bib98]\]. Other less reported CQ and HCQ toxicities include urticaria \[[@bib99]\], ototoxicity \[[@bib100],[@bib101]\] and some neurological effects \[[@bib102],[@bib103]\].

5. *In vitro* antiviral activity of CQ and HCQ {#sec5}
==============================================

The antiviral effects of CQ were suggested at least 50 years ago \[[@bib23],[@bib25]\]. Since then, several studies have tested the ability of CQ and HCQ to inhibit the replication of a wide range of CoVs and non-CoV viruses *in vitro* as shown in [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"} , respectively. The majority of these studies have revealed a substantial ability of CQ and HCQ as well as some of their derivatives to inhibit viral replication with no to low toxicity. Specifically, CQ has been shown to inhibit the replication of different CoVs including SARS-CoV, MERS-CoV and SARS-CoV-2 among others in several studies ([Table 2](#tbl2){ref-type="table"}) \[[@bib37],[@bib104], [@bib105], [@bib106], [@bib107], [@bib108], [@bib109], [@bib110], [@bib111], [@bib112], [@bib113], [@bib114], [@bib115]\]. Only two studies showed no significant inhibitory effects of CQ on MERS-CoV and mouse hepatitis virus (MHV4) \[[@bib116],[@bib117]\]. Other CQ derivatives such as amodiaquine (AMD), ferroquine (FQ), hydroxy ferroquine (HFQ) have been also shown to exerts some antiviral activity \[[@bib105],[@bib106]\]. Interestingly enough, while HCQ does not seem to have a significant effect in reducing SARS-CoV and Feline CoV replication \[[@bib106]\], it was recently shown to have a potent *in vitro* inhibitory effects against SARS-CoV-2 replication \[[@bib112],[@bib116]\].Table 2*In vitro* antiviral activity of CQ and its derivatives on CoVs.Table 2DrugVirusCellsEC~50~ (μM)SIMain findingsYearRefCQSARS-CoVVero E68·8 ± 1·230↓ viral replication2004\[[@bib104]\]CQSARS-CoVVero E64.4 + 1·0--↓ viral replication2005\[[@bib37]\]CQSARS-CoVVero 761--52--20↓ viral replication2006\[[@bib105]\]CQSARS-CoVVero6.5 ± 3.2\>15↓ viral replication2006\[[@bib106]\]CQSARS-CoVVero E64.1 ± 1.0\>31↓ viral replication2014\[[@bib107]\]CQ-MPSARS-CoVVero 764--63--8↓ viral replication2006\[[@bib105]\]CQ-DPSARS-CoVVero 763--82--10↓ viral replication2006\[[@bib105]\]AMDSARS-CoVVero 763--102--10↓ viral replication2006\[[@bib105]\]HCQSARS-CoVVero34 ± 5\>3Ineffective2006\[[@bib106]\]FQSARS-CoVVero1.4 ± 0.115↓ viral replication2006\[[@bib106]\]HFQSARS-CoVVero1.9--4.94--17↓ viral replication2006\[[@bib106]\]CQMERS-CoVHuh73.0 ± 1.119.4↓ viral replication2014\[[@bib107]\]CQMERS-CoVVero E66.3--Ineffective2018\[[@bib116]\]CQSARS-CoV-2Vero E61.13\>88.5↓ viral replication2020\[[@bib113]\]CQSARS-CoV-2Vero5.47--↓ viral replication2020\[[@bib112]\]CQ[a](#tbl2fna){ref-type="table-fn"}SARS-CoV-2Vero E62.71--7.3637.12--100.81↓ viral replication2020\[[@bib114]\]HCQSARS-CoV-2Vero0.72--↓ viral replication2020\[[@bib112]\]HCQ[a](#tbl2fna){ref-type="table-fn"}SARS-CoV-2Vero E64.06--17.3114.41--61.45↓ viral replication2020\[[@bib114]\]CQHCoV-229EL132----↓ viral replication2008\[[@bib109]\]CQHCoV-229EHuh73.3 ± 1.2\>15↓ viral replication2014\[[@bib107]\]CQHCoV-OC43HRT-180.3 ± 0.01369↓ viral replication2009\[[@bib108]\]CQMHV4Murine cells----Ineffective1991\[[@bib117]\]CQMHV3Murine MΦ----↓ viral replication1966\[[@bib115]\]CQF--CoVCRFK\>0.8--↓ viral replication2006\[[@bib106]\]HCQF--CoVCRFK28 ± 27--Ineffective2006\[[@bib106]\]FQF--CoVCRFK2.9 ± 1.2--↓ viral replication2006\[[@bib106]\]HFQF--CoVCRFK\>4--Weak effect2006\[[@bib106]\]CQFIPVfcwf-4----↓ viral replication2013\[[@bib110]\]CQPHEVNeuro-2a----↓ viral replication2017\[[@bib111]\][^2][^3]Table 3*In vitro* antiviral activity of CQ and its derivatives on non-CoVs.Table 3DrugVirusCellsEC~50~ (μM)SIMain findingsYearRefCQHIV-1HL3Tl----↑ viral replication[p](#tbl3fnp){ref-type="table-fn"}1988\[[@bib126]\]CQHIV-1H-9--low toxicity↓ viral replication1990\[[@bib118]\]CQ[a](#tbl3fna){ref-type="table-fn"}HIV-1H-9--No toxicity↓ viral replication1998\[[@bib119]\]CQ[a](#tbl3fna){ref-type="table-fn"}HIV-1U-937--No toxicity↓ viral replication1998\[[@bib119]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1H-90.9No toxicity↓ viral replication1999\[[@bib120]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1U-9370.4No toxicity↓ viral replication1999\[[@bib120]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1T cells[k](#tbl3fnk){ref-type="table-fn"}0.9No toxicity↓ viral replication1999\[[@bib120]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1Monocytes[k](#tbl3fnk){ref-type="table-fn"}0.2No toxicity↓ viral replication1999\[[@bib120]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1U-1[l](#tbl3fnl){ref-type="table-fn"}0.1No toxicity↓ viral replication1999\[[@bib120]\]CQ[b](#tbl3fnb){ref-type="table-fn"}HIV-1ACH-2[m](#tbl3fnm){ref-type="table-fn"}1No toxicity↓ viral replication1999\[[@bib120]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1U-9370.4No toxicity↓ viral replication2001\[[@bib121]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1H-90.9No toxicity↓ viral replication2001\[[@bib121]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1T cells[k](#tbl3fnk){ref-type="table-fn"}0.9No toxicity↓ viral replication2001\[[@bib121]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1MΦ[k](#tbl3fnk){ref-type="table-fn"}0.2No toxicity↓ viral replication2001\[[@bib121]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1U-1[l](#tbl3fnl){ref-type="table-fn"}0.1No toxicity↓ viral replication2001\[[@bib121]\]CQ[c](#tbl3fnc){ref-type="table-fn"}HIV-1ACH-2[m](#tbl3fnm){ref-type="table-fn"}1No toxicity↓ viral replication2001\[[@bib121]\]CQ[d](#tbl3fnd){ref-type="table-fn"}HIV-1H-91--10No toxicity↓ viral replication2004\[[@bib122]\]CQHIV-1MT-48.86 ± 1.186↓ viral replication2006\[[@bib106]\] [r](#tbl3fnr){ref-type="table-fn"}HCQHIV-1U-9371low toxicity↓ viral replication1993\[[@bib123]\]HCQHIV-1CEM10low toxicity↓ viral replication1993\[[@bib123]\]HCQHIV-1630.01No toxicity↓ viral replication1996\[[@bib124]\]HCQHIV-1SP0.1No toxicity↓ viral replication1996\[[@bib124]\]HCQHIV-163~HIV~----↓ viral replication1996\[[@bib124]\]HCQHIV-1SPH----↓ viral replication1996\[[@bib124]\]HCQHIV-1MT-4\>12--Ineffective2006\[[@bib106]\] [r](#tbl3fnr){ref-type="table-fn"}FQHIV-1MT-4\>2.4--Ineffective2006\[[@bib106]\] [r](#tbl3fnr){ref-type="table-fn"}HFQHIV-1MT-42.9 ± 1.13↓ viral replication2006\[[@bib106]\]CQ[d](#tbl3fnd){ref-type="table-fn"}HIV-2MT-41--10No toxicity↓ viral replication2004\[[@bib122]\]CQIAV H1N1MDCK----↓ viral replication1981\[[@bib127]\]CQIAV H1N1MDCK3.60--↓ viral replication2006\[[@bib128]\]CQIAV H1N1A549----↓ viral replication2007\[[@bib129]\]CQIAV H1N1MDCK1.26--↓ viral replication2007\[[@bib130]\]CQIAV H3N2MDCK0.84--↓ viral replication2006\[[@bib128]\]CQIAV H3N2MDCK1.53--↓ viral replication2007\[[@bib130]\]CQIAV H3N2A549----↓ viral replication2007\[[@bib129]\]CQIAV H5N1A549----↓ viral replication2013\[[@bib29]\]CQIAV H5N9MDCK14.38--↓ viral replication2007\[[@bib130]\]CQIAV H7N3[f](#tbl3fnf){ref-type="table-fn"}[h](#tbl3fnh){ref-type="table-fn"}MDCK\>20--Ineffective2007\[[@bib130]\]CQIAV H7N3[g](#tbl3fng){ref-type="table-fn"}[h](#tbl3fnh){ref-type="table-fn"}MDCK14.39--↓ viral replication2007\[[@bib130]\]CQFlu BMDCK----↓ viral replication1983\[[@bib131]\]CQDENV-2BHK----↓ viral replication[q](#tbl3fnq){ref-type="table-fn"}1990\[[@bib43]\]CQDENV-2Vero--No toxicity↓ viral replication2013\[[@bib141]\]CQDENV-2C6/36--No toxicityIneffective2013\[[@bib141]\]CQDENV-2U-937--No toxicity↓ viral replication2014\[[@bib140]\]CQZIKVVero9.82No toxicity↓ viral replication2016\[[@bib135]\]CQZIKVhBMECs14.20No toxicity↓ viral replication2016\[[@bib135]\]CQZIKVNSCs12.36No toxicity↓ viral replication2016\[[@bib135]\]CQZIKVNSs----↓ viral replication2016\[[@bib135]\]CQZIKVVero4.15--↓ viral replication2017\[[@bib134]\]CQZIKVHuh71.72--2.72--↓ viral replication2017\[[@bib134]\]CQZIKVNSs10--↓ viral replication2017\[[@bib136]\]AMDZIKVVero----↓ viral replication2017\[[@bib134]\]CQCHIKVHeLa----↓ viral replication2007\[[@bib132]\]CQ preCHIKVVero7.0 ± 1.537.14↓ viral replication2010\[[@bib41]\]CQ postCHIKVVero17.2 ± 2.115.29↓ viral replication2010\[[@bib41]\]CQ conCHIKVVero10.0 ± 1.226↓ viral replication2010\[[@bib41]\]CQCHIKVMDM[n](#tbl3fnn){ref-type="table-fn"}--low toxicity↓ viral replication2018\[[@bib133]\]CQCHIKVFibroblasts[n](#tbl3fnn){ref-type="table-fn"}--high toxicity↓ viral replication2018\[[@bib133]\]CQEBOV[i](#tbl3fni){ref-type="table-fn"}HEK 293T4.7--↓ viral replication2013\[[@bib139]\]CQEBOV[j](#tbl3fnj){ref-type="table-fn"}Vero 7616--↓ viral replication2013\[[@bib139]\]HCQEBOV[i](#tbl3fni){ref-type="table-fn"}HEK 293T9.5--↓ viral replication2013\[[@bib139]\]HCQEBOV[j](#tbl3fnj){ref-type="table-fn"}Vero 7622--↓ viral replication2013\[[@bib139]\]AMDEBOV[i](#tbl3fni){ref-type="table-fn"}HEK 293T2.6--↓ viral replication2013\[[@bib139]\]AMDEBOV[j](#tbl3fnj){ref-type="table-fn"}Vero 768.4--↓ viral replication2013\[[@bib139]\]AQEBOV[i](#tbl3fni){ref-type="table-fn"}HEK 293T4.3--↓ viral replication2013\[[@bib139]\]AQEBOV[j](#tbl3fnj){ref-type="table-fn"}Vero 7621--↓ viral replication2013\[[@bib139]\]CQEBOVMRC-5--low toxicity↓ viral replication2015\[[@bib137]\]CQEBOVVero E61.77[o](#tbl3fno){ref-type="table-fn"}--↓ viral replication2015\[[@bib138]\]CQSINVBHK-21----↓ viral replication1981\[[@bib142]\]CQVSVBHK-21----↓ viral replication1981\[[@bib142]\]CQVSVB104----↓ viral replication2010\[[@bib149]\]CQRabiesNS-20----↓ viral replication1984\[[@bib143]\]CQPICVBHK-21↓ viral replication1989\[[@bib147]\]CQPoliovirusHeLa----Ineffective1991\[[@bib151]\]CQSLEBHK----↓ viral replication[q](#tbl3fnq){ref-type="table-fn"}1990\[[@bib43]\]CQPOWBHK----↓ viral replication[q](#tbl3fnq){ref-type="table-fn"}1990\[[@bib43]\]CQNiVVero----↓ viral replication2009\[[@bib150]\]CQNiVHeLa0.62--↓ viral replication2010\[[@bib148]\]CQHeVVero----↓ viral replication2009\[[@bib150]\]CQHeVHeLa0.71--↓ viral replication2010\[[@bib148]\]CQEBVHH514-16----↑ viral replication2017\[[@bib125]\]CQ[e](#tbl3fne){ref-type="table-fn"}HCVHuh-70.22--↓ viral replication2010\[[@bib144]\]CQDHBVPDH----↓ viral replication1990\[[@bib145]\]CQDHBVPDH--No toxicity↓ viral replication1991\[[@bib146]\]CQJEVB104----↓ viral replication2010\[[@bib149]\]CQMARV[i](#tbl3fni){ref-type="table-fn"}HEK 293T5.5--↓ viral replication2013\[[@bib139]\]CQMARV[j](#tbl3fnj){ref-type="table-fn"}Vero 7615--↓ viral replication2013\[[@bib139]\]HCQMARV[i](#tbl3fni){ref-type="table-fn"}HEK 293T9.8--↓ viral replication2013\[[@bib139]\]HCQMARV[j](#tbl3fnj){ref-type="table-fn"}Vero 7618--↓ viral replication2013\[[@bib139]\]AMDMARV[i](#tbl3fni){ref-type="table-fn"}HEK 293T2.3--↓ viral replication2013\[[@bib139]\]AMDMARV[j](#tbl3fnj){ref-type="table-fn"}Vero 768.3--↓ viral replication2013\[[@bib139]\]AQMARV[i](#tbl3fni){ref-type="table-fn"}HEK 293T4.3--↓ viral replication2013\[[@bib139]\]AQMARV[j](#tbl3fnj){ref-type="table-fn"}Vero 7642--↓ viral replication2013\[[@bib139]\]CQCCHFVVero E6----↓ viral replication2015\[[@bib150]\]CQCCHFVHuh7--21.3↓ viral replication2015\[[@bib150]\][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22]

Similarly, these compounds have shown excellent *in vitro* antiviral activity against several non CoV (mostly RNA viruses) with low toxicity in most cases ([Table 3](#tbl3){ref-type="table"}). For instance, HIV was shown to be inhibited by CQ alone or in combination with HCQ, hydroxyurea (HU1), didanosine (ddI), zidovudine (ZDV), indinavir (IDV), saquinavir (SQV) or ritonavir (RTV) \[[@bib106],[@bib118], [@bib119], [@bib120], [@bib121], [@bib122]\]. While other derivatives such as HCQ and HFQ have been also shown to inhibit HIV replication \[[@bib106],[@bib123],[@bib124]\], one study showed no effect of HCQ and FQ on HIV \[[@bib106]\]. Similarly, it was found that CQ could enhance Epstein-Barr virus replication \[[@bib125]\]. Furthermore, another study has suggested possible enhanced HIV replication with CQ treatment through protection of tat protein from proteolytic degradation \[[@bib126]\]. Influenza A and B viruses have also been shown to be inhibited by CQ \[[@bib27],[@bib127], [@bib128], [@bib129], [@bib130], [@bib131]\] although contradicting results have been seen for some subtypes and strains such as avian H7N3 strains (A/Mallard/It/43/01 and A/Ty/It/220158/02) \[[@bib106],[@bib130]\]. Several other studies have also reported *in vitro* inhibitory effect of CQ on multiple viruses such as chikungunya virus (CHIKV) \[[@bib41],[@bib132],[@bib133]\], zika virus (ZIKV) \[[@bib134], [@bib135], [@bib136]\], Ebola virus (EBOV) \[[@bib137], [@bib138], [@bib139]\], dengue viruses (DENV) in mammalian cells \[[@bib43],[@bib140],[@bib141]\] but not insect cells \[[@bib141]\] as well as several others \[[@bib43],[@bib139],[@bib142], [@bib143], [@bib144], [@bib145], [@bib146], [@bib147], [@bib148], [@bib149], [@bib150]\]. Nonetheless, some reports failed to observe antiviral activity of CQ, HCQ and FQ on several other viruses including polio virus, reovirus, respiratory syncytial virus (RSV), herpes simplex viruses, coxsackie virus, vesicular stomatitis virus (VSV), vaccinia virus, sindbis virus, parainfluenza-3 virus and Punta Toro virus \[[@bib106],[@bib151]\].

6. *In vivo* animal antiviral activity of CQ and HCQ {#sec6}
====================================================

There are limited studies established to investigate the possible antiviral effects of CQ or HCQ in animal models ([Table 4](#tbl4){ref-type="table"} ). In general, studies showed no significant effect of CQ on CoVs including SARS-CoV and feline infectious peritonitis virus (FIPV) replication or clinical scores in mice and cats, respectively \[[@bib105],[@bib110]\]. However, it has been found that CQ significantly reduced HCoV-OC43 dissemination and replication in mice central nervous system (CNS) \[[@bib152]\] and increased the survival rate of HCoV-OC43 infected newborn mice when their mothers treated by CQ most probably through placental and maternal milk transfer \[[@bib108]\].Table 4*In vivo* animal studies on the antiviral activity of CQ and its derivatives on CoVs and non-CoVs.Table 4DrugVirusModelDose (mg/kg)RouteMain findingsYearRef**CoVs**CQSARS-CoVMice1--50i.p or i.n.Tolerated; ineffective2006\[[@bib105]\]AMDSARS-CoVMice9.4--75i.p or i.n.Tolerated; ineffective2006\[[@bib105]\]CQHCoV-OC43Mice15 (daily)s.c.Effective[c](#tbl4fnc){ref-type="table-fn"}2009\[[@bib108]\]CQHCoV-OC43Mice30 then 15s.c.Effective2019\[[@bib152]\]CQFIPVCat10/3 dayss.c.Not significant effect2013\[[@bib110]\]**Non CoVs**CQIAV H1N1Mice12.5 (daily)i.t. or oralToxic; ineffective2007\[[@bib129]\]CQIAV H3N2Mice12.5--37.5 (daily)i.t. or oralToxic; ineffective2007\[[@bib129]\]CQIAV H3N2Ferrets10 (daily)oralIneffective2007\[[@bib129]\]CQIAV H5N1Mice50i.p.Effective[d](#tbl4fnd){ref-type="table-fn"}2013\[[@bib29]\]CQEBOVGUPI33.75 (2 daily)i.v. or oralToxic; ineffective2015\[[@bib137]\]CQEBOVMice90i.p.Toxic; ineffective2015\[[@bib138]\]CQEBOVHamsters90i.p.Toxic; ineffective2015\[[@bib138]\]CQ[a](#tbl4fna){ref-type="table-fn"}EBOVHamsters50i.p.Tolerated; ineffective2015\[[@bib138]\]CQEBOVMice90i.pEffective2013\[[@bib139]\]CQNiVFerrets25 (daily)--Ineffective2009\[[@bib153]\]CQ[b](#tbl4fnb){ref-type="table-fn"}NiVHamsters50i.p.Ineffective[e](#tbl4fne){ref-type="table-fn"}2010\[[@bib148]\]CQ[b](#tbl4fnb){ref-type="table-fn"}HeVHamsters50/2 daysi.p.Ineffective[e](#tbl4fne){ref-type="table-fn"}2010\[[@bib148]\]CQLASVMice90i.pIneffective2013\[[@bib139]\]CQZIKVMice100i.g.Effective[f](#tbl4fnf){ref-type="table-fn"}2017\[[@bib134]\]CQZIKVMice50 (5 days)oralEffective[g](#tbl4fng){ref-type="table-fn"}2017\[[@bib136]\]CQCHIKVNHP14 (daily)s.c.Toxic; ineffective[h](#tbl4fnh){ref-type="table-fn"}2018\[[@bib133]\]CQSFVMice\~10i.pToxic; ineffective1991\[[@bib154]\][^23][^24][^25][^26][^27][^28][^29][^30][^31]

On the other hand, CQ administration has shown contradicting outcomes when used against non-CoVs RNA viruses in different animal models. Some studies have demonstrated antiviral efficacy of CQ in influenza A virus H5N1, ZIKV and EBOV infected mice \[[@bib29],[@bib134],[@bib139]\]. Interestingly, CQ was effective against ZIKV in both wild type and IFNAR deficient mice, and protected infected suckling pups from infection and microcephaly when given to their mothers \[[@bib29],[@bib134],[@bib136]\]. However, several other studies showed no significant antiviral effect of CQ against influenza A H1N1 and H3N2 viruses in mice and Ferrets, respectively \[[@bib129]\]. Similarly, CQ was ineffective against EBOV in guinea pigs, mice and hamsters \[[@bib137],[@bib138]\], Nipah virus (NiV) in Ferrets and hamsters \[[@bib148],[@bib153]\], Hendra virus (HeV) in hamsters \[[@bib148]\], CHIKV in cynomolgus macaques \[[@bib133]\], Lassa virus (LASV) in mice \[[@bib139]\] and Semliki Forest Virus (SIV) in mice \[[@bib154]\]. Importantly, most of these previous *in vivo* studies showed toxicity in animals \[[@bib129],[@bib133],[@bib137],[@bib138],[@bib154]\]. Furthermore, it was shown that CQ could lead to disease exacerbation correlating with increased type I IFN response and delayed immune responses in CHIKV infected macaques \[[@bib133]\], increased mortality rate of SFV-infected mice \[[@bib154]\] and NiV or HeV infected hamsters \[[@bib148]\].

7. Use of CQ and HCQ as antiviral agents in clinical trials {#sec7}
===========================================================

There are very limited published clinical trials that studied the possible antiviral effects of CQ or HCQ in CoV and non-CoV infected patients ([Table 5](#tbl5){ref-type="table"} ). These published clinical trials have clearly shown no significant benefit of using CQ in the prevention or treatment against influenza, DENV or CHIKV infections in patients \[[@bib133],[@bib155], [@bib156], [@bib157], [@bib158]\]. In fact, in one study, patients treated with CQ were more likely to develop adverse effects such as arthralgia at day 200 post-treatment \[[@bib157]\]. On the other hand, few studies have reported that HCQ could decease HIV-1 viremia, stabilize CD4 T cell count and reduce IL-6 and IgG levels in infected patients \[[@bib159]\], although others showed contradicting finding of increased HIV RNAemia in HCQ treated patients \[[@bib160],[@bib161]\]. Interestingly, while few clinical studies have suggested that the use of HCQ alone or with azithromycin (AZT) could be beneficial for COVID-19 patients as it reduces viral shedding and time to clinical recovery \[[@bib162], [@bib163], [@bib164]\], others have reported no effect in infected patients \[[@bib165],[@bib166]\]. However, it is important to note that most of these studies have several limitations in study designs with small sample sizes. Nonetheless, around 104 clinical trials are ongoing in different countries to asses and evaluate the therapeutic and prophylactic effects of both CQ and/or HCQ in COVID-19 patients ([Table 6](#tbl6){ref-type="table"} ).Table 5Main findings of clinical trials on the antiviral activity of CQ and its derivatives on CoVs and non-CoVs.Table 5DrugVirusDesignDose mg/dayTotal No.Main FindingsYear RefHCQ + AZTSARS-CoV-2SAOLS600 mg/day (10 days)42↓ viral load[a](#tbl5fna){ref-type="table-fn"}2020 \[[@bib162]\]HCQSARS-CoV-2RCT400 mg/day (5 days)62↓ Recovery time2020 \[[@bib163]\]HCQSARS-CoV-2Pilot400 mg/day (5 days)30Ineffective[b](#tbl5fnb){ref-type="table-fn"}2020 \[[@bib165]\]HCQ + AZTSARS-CoV-2OS600 mg/day (10 days)80↓ viral load2020 \[[@bib164]\]HCQ + AZTSARS-CoV-2SAOLS600 mg/day (10 days)11Ineffective[c](#tbl5fnc){ref-type="table-fn"}2020 \[[@bib166]\]CQInfluenza A/BRDBPCS500 mg/day (1 week)\
Once a week (11 weeks)1516Ineffective2011 \[[@bib155]\]CQDENVRDBPCS600 mg/day (day 1 and 2)\
300 mg/day (day 3)307Ineffective[d](#tbl5fnd){ref-type="table-fn"}2010 \[[@bib156]\]CQDENVRDBPCS500 mg/day BID (3 days)37Ineffective[e](#tbl5fne){ref-type="table-fn"}2013 \[[@bib158]\]CQCHIKVRDBPCS600 mg (day 1)\
300 mg (BID, days 2 and 3)\
300 mg (days 4 and 5)54Ineffective[f](#tbl5fnf){ref-type="table-fn"}2008 \[[@bib157]\]\
2018 \[[@bib133]\]HCQHIV 1Case report600 mg/day2↓ viral load[g](#tbl5fng){ref-type="table-fn"}1996 \[[@bib169]\]HCQHIV 1RDBPCS800 mg/day (8 weeks)40↓ viral load\
Stable CD4^+^ level\
↓ serum IL-6 & IgG1995 \[[@bib170]\]HCQHIV 1RDBS800 mg/day (16 weeks)72↓ viral load\
Stable CD4^+^ level\
↓ serum IL-6 & IgG1997 \[[@bib159]\]HCQHIVRDBPCS400 mg/day (42 weeks)83Ineffective\
↑ viral load\
↓ CD4^+^ level2012 \[[@bib161]\]CQ -- ARTHIVRDBPCS250 mg/day (12 weeks)33↑ viral replication2016 \[[@bib171]\]CQ + ARTHIVRDBPCS250 mg/day (12 weeks)37↓ Immune cell activation2016 \[[@bib171]\][^32][^33][^34][^35][^36][^37][^38][^39]Table 6Characteristics of ongoing clinical trials studying the efficacy and safety of CQ and HCQ in patients with COVID-19.Table 6DrugDesignStatusGroup(s)Total NoPrimary outcomesCountry\
Registration No.HCQInterventional\
ROLCSCompletedConventional treatment\
HCQ360Viral clearanceChina\
ChiCTR2000029868HCQInterventional\
ROLCSRecruitingConventional treatment\
HCQ78Clinical statusChina\
ChiCTR2000029740HCQInterventional RDBSRecruitingPlacebo\
HCQ300Viral clearance\
T cell recovery timeChina\
ChiCTR2000029559HCQRetrospective ObservationalNot yet recruitingHCQ1200Pneumonia incidenceChina\
ChiCTR2000031782HCQInterventional ROLSCompletedConventional treatment\
HCQ30Viral clearance\
MortalityChina\
NCT04261517CQInterventional\
RROLCSRecruitingControl\
CQ80Clinical recovery timeChina\
ChiCTR2000030718CQInterventional\
RCTRecruitingPlacebo\
CQ/FAV\
FAV150Improvement or recovery Viral clearanceChina\
ChiCTR2000030987CQInterventional\
RRSBCSRecruitingPlacebo\
CQ300Viral clearanceChina\
ChiCTR2000031204CQInterventional\
ROLCSNot yet recruitingHCQ\
Arbidol320No. patients progressed to suspected/confirmedChina\
ChiCTR2000029803CQInterventional\
RSBCSRecruitingConventional/CQ\
CQ100Length of hospital stayChina\
ChiCTR2000029939CQInterventional\
SAOLSRecruitingConventional/CQ100Length of hospital stayChina\
ChiCTR2000029935CQInterventional\
OLSNot yet recruitingLPV/RTV\
CQ/LPV/RTV\
CQ205Viral clearanceChina\
ChiCTR2000029609CQInterventional cohort studyRecruitingConventional treatment\
CQ20Viral clearance\
MortalityChina\
ChiCTR2000029542CQInterventional\
ROLCSRecruitingLPV/RTV\
CQ112Clinical status\
Mortality\
Viral clearanceChina\
ChiCTR2000029741CQInterventional OLSRecruitingControl\
CQ80Clinical recovery timeChina\
ChiCTR2000029988CQInterventional SAOLSNot yet recruitingCQ10Viral clearance\
MortalityChina\
ChiCTR2000029975CQInterventional RDBPCSRecruitingPlacebo\
FAV\
CQ/FAV150Time to and frequency of improvement or recovery\
Viral clearanceChina\
NCT04319900CQInterventional ROLCSNot yet recruitingCarrimycin\
CQ\
LPV/RTV\
Arbidol520Fever\
HRCT\
Viral clearanceChina\
NCT04286503HCQ CQInterventional\
ROLCSRecruitingCQ\
HCQ100Clinical recovery timeChina\
ChiCTR2000029899HCQ CQInterventional\
ROLCSRecruitingCQ\
HCQ100Clinical recovery timeChina\
ChiCTR2000029898HCQ CQInterventional\
ROLSNot yet recruitingConventional treatment\
HCQ\
CQ100Clinical recovery timeChina\
ChiCTR2000030054HCQ CQInterventional ROLSNot yet recruitingConventional treatment\
CQ\
HCQ100Clinical recovery time\
Viral clearanceChina\
ChiCTR2000029992HCQInterventional RCTNot yet recruitingPlacebo\
HCQ1600No. symptomatic confirmed casesUSA\
NCT04318444HCQInterventional\
ROLSNot yet recruitingStandard of care\
HCQ\
AZT\
HCQ/AZT500Clinical statusUSA\
NCT04335552HCQInterventional OLSNot yet recruitingHCQ\
Vit C\
Vit D\
Zinc600Viral clearance\
Blood pressure\
Presence of side effectsUSA\
NCT04335084HCQInterventional RCTRecruitingHCQ\
Vit C1250Hospitalization\
IMVUSA\
NCT04334967HCQInterventional OLSNot yet recruitingHCQ/AZT/Vit C/Vit D/Zinc60Symptoms resolution\
Viral clearance\
SafetyUSA\
NCT04334512HCQInterventional ROLSRecruitingHCQ\
AZT1550Hospital admissionUSA\
NCT04334382HCQInterventional RDBPCSRecruitingPlacebo\
HCQ210Viral clearanceUSA\
NCT04333654HCQInterventional OLSRecruitingHCQ\
Control360Rate of positivityUSA\
NCT04333225HCQInterventional\
ROLSNot yet recruitingStandard of care\
HCQ\
HCQ/AZT160Viral clearanceUSA\
NCT04336332HCQInterventional\
RDBPCSRecruitingPlacebo\
HCQ510Clinical statusUSA\
NCT04332991HCQInterventional\
RDBPCS\
ROLCSNot yet recruitingPlacebo\
HCQ400Quarantine release rate\
Hospital discharge rate\
Infection rateUSA\
NCT04329923HCQInterventional RCTRecruitingPlacebo\
HCQ3500Survival/recoveryUSA\
NCT04328467HCQInterventional RDBPCSRecruitingPlacebo\
HCQ\
LPV/RTV\
LST4000Clinical statusUSA\
NCT04328012HCQInterventional\
ROLSRecruitingHCQ\
AZT300Clinical statusUSA\
NCT04329832HCQInterventional RSBSNot yet recruitingAscorbic Acid\
HCQ2000Viral clearanceUSA\
NCT04328961HCQ\
CQInterventional ROLCSRecruitingHCQ\
HCQ/AZT\
CQ\
CQ/AZT500RecoveryUSA\
NCT04341727HCQInterventional RCTRecruitingPlacebo\
HCQ3000Incidence in asymptomatic\
SeverityUSA/Canada\
NCT04308668HCQ\
CQInterventional\
RDBPCSNot yet recruitingPlacebo\
CQ\
HCQ55000Disease severityUSA, Australia, Canada, Ireland, South Africa, UK\
NCT04333732HCQInterventional OLSNot yet recruitingStandard of care\
LPV/RTV\
HCQ\
Baricitinib\
Sarilumab1000Clinical statusCanada\
NCT04321993HCQInterventional RDBPCSNot yet recruitingPlacebo\
HCQ1660Hospitalization\
IMV\
MortalityCanada\
NCT04329611CQInterventional ROLCSNot yet recruitingStandard of care\
CQ/AZT1500Outpatients: admission or death\
Inpatients: IMV or deathCanada\
NCT04324463HCQInterventional RDBPCSNot yet recruitingPlacebo\
HCQ\
LPV/RTV1200Confirmed infection in HCWFrance\
NCT04328285HCQInterventional RDBPCSRecruitingPlacebo\
HCQ1300Mortality\
IMVFrance\
NCT04325893HCQInterventional ROLSRecruitingStandard of care\
RDV\
LPV/RTV\
LPV/RTV/IFβ-1a\
HCQ3100Clinical statusFrance\
NCT04315948HCQInterventional ROLCSRecruitingRDV\
LPV/RTV\
IFβ-1a\
HCQ3100Clinical statusFrance\
EudraCT 2020-000936-23HCQ--RecruitingHCQ25Viral clearanceFrance\
EudraCT 2020-000890-25HCQInterventional OLCSRecruitingStandard of care\
HCQ/AZT1000Incidence\
MortalityFrance\
EudraCT 2020-001250-21HCQInterventional RDBPCSRecruitingPlacebo\
HCQ1300IMV\
DeathFrance\
EudraCT 2020-001271-33HCQ--RecruitingHCQ50HCQ pharmacokineticsFrance\
EudraCT 2020-001281-11CQInterventional CSSRecruitingAny drug used to treat Covid-19 including CQ1000Renal failureFrance\
NCT04314817CQInterventional ROLCSRecruitingStandard of care\
CQ analogue\
NIVO\
TCZ273Survival rateFrance\
NCT04333914HCQInterventional RDBSNot yet recruitingHCQ/LPV/RTV\
HCQ/LPV/RTV/LEV/BUD/FORM30Chest CT-scan\
Viral clearanceIran\
NCT04331470HCQInterventional ROLCSRecruitingHCQ/LPV/RTV\
HCQ/LPV/RTV/IFβ-1b30Clinical status\
Lab/radiological findings Adverse reactionsIran\
IRCT20100228003449N27HCQInterventional ROLCSRecruitingHCQ/LPV/RTV\
HCQ/LPV/RTV/IFβ-1a30Clinical status\
Lab/radiological findings Adverse reactionsIran\
IRCT20100228003449N28HCQInterventional ROLCSRecruitingHCQ/LPV/RTV\
HCQ/LPV/RTV/SOF/LDV50Clinical status\
Lab/radiological findings Adverse reactionsIran\
IRCT20100228003449N29HCQInterventional SAOLSRecruitment completedHCQ/OTV/LPV/RTV/IFβ-1a20Clinical statusIran\
IRCT20151227025726N12HCQInterventional SAOLSRecruitingHCQ/LPV/RTV\
HCQ/ATV/RTV50Clinical status\
Lab/radiological findings Adverse reactionsIran\
IRCT20100228003449N30HCQInterventional ROLCSNot yet recruitingStandard of care\
HCQ\
HCQ/AZT630Clinical statusBrazil\
NCT04322123HCQInterventional ROLSRecruitingHCQ\
HCQ/AZT440Clinical statusBrazil\
NCT04321278HCQInterventional\
OLSNot yet recruitingHCQ/AZT400Evolution of ARS, SpO2, hemodynamic stabilityBrazil\
NCT04329572CQInterventional RDBSRecruitingLow Dose CQ\
High Dose CQ440MortalityBrazil\
NCT04323527HCQInterventional OLCSNot yet recruitingRDV\
HCQ\
HCQ/RDV700MortalityNorway\
NCT04321616HCQInterventional ROLCSRecruitingStandard of care\
HCQ202Viral clearanceNorway\
NCT04316377HCQInterventional RCTRecruitingStandard of care\
HCQ/RDV443Safety and efficacyNorway\
EudraCT 2020-000982-18HCQInterventional ROLCSRecruitingStandard of care\
HCQ200Viral clearanceNorway\
EudraCT 2020-001010-38HCQInterventional ROLCSRecruitingStandard measures\
HCQ/DRV/COBI3040Incidence of secondary casesSpain\
NCT04304053HCQInterventional\
RDBPCSNot yet recruitingPlacebo\
HCQ\
TDF/FTC\
HCQ/TDF/FTC4000Confirmed symptomatic infectionsSpain\
NCT04334928HCQInterventional RDBPCSRecruitingPlacebo\
HCQ440No. confirmed casesSpain\
NCT04331834HCQInterventional ROLCSRecruitingHCQ/AZT\
HCQ/AZT/TCZ276Mortality\
IMVSpain\
NCT04332094HCQInterventional ROLCSRecruitingLPV/RTV\
Dexamethasone\
IFβ-1a\
HCQ2000MortalityUK\
EudraCT 2020-001113-21[a](#tbl6fna){ref-type="table-fn"}HCQInterventional ROLCSRecruitingStandard of care\
HCQ350Change in SpO2/FiO2UK\
EudraCT 2020-001270-29HCQInterventional RPCSRecruitingPlacebo\
HCQ3000Hospital admission\
MortalityUK\
EudraCT 2020-001209-22HCD\
CQInterventional RDBPCSNot yet recruitingPlacebo\
CQ or HCQ40,000No. symptoms\
SeverityUK\
NCT04303507HCQInterventional ROLCSRecruitingNo intervention control\
LPV/RTV\
HCQ150Viral clearanceKorea\
NCT04307693HCQInterventional ROLCSNot yet recruitingControl\
CIC\
HCQ/CIC141Viral clearanceKorea\
NCT04330586HCQInterventional\
RCTNot yet recruitingControl\
HCQ2486IncidenceKorea\
NCT04330144HCQInterventional RPCSNot yet recruitingPlacebo\
HCQ2700Clinical statusGermany\
NCT04340544HCQInterventional RPCSRecruitingPlacebo\
HCQ220Viral clearanceGermany\
NCT04342221HCQInterventional\
RPCSNot yet recruitingPlacebo/HCQ\
HCQ/COBI334Hospital admissionGermany\
NCT04338906HCQInterventional RDBPCSOngoingPlacebo\
HCQ220Viral clearanceGermany\
EudraCT 2020-001224-33HCQSAOLSRecruitingHCQ150Dose optimizationAustralia\
ACTRN12620000447954HCQInterventional\
RCTNot yet recruitingControl\
HCQ\
LPV/RTV\
HCQ/LPV/RTV2500No. patients not admitted to ICUAustralia\
ACTRN12620000445976CQInterventional\
ROLCSNot yet recruitingCQ680Sick days of HCWAustralia\
ACTRN12620000417987HCQInterventional RTBCSNot yet recruitingPlacebo\
HCQ400Infection rateMexico\
NCT04318015HCQInterventional RDBPCSNot yet recruitingPlacebo\
HCQ500MortalityMexico\
NCT04315896HCQInterventional ROLCSNot yet recruitingControl\
HCQ1116Development of severe infection or deathIsrael\
NCT04323631CQInterventional ROLSNot yet recruitingStandard of care\
CQ210Viral clearance\
Clinical statusIsrael\
NCT04333628HCQObservational\
CCPSRecruitingHCQ80ProtectionTurkey\
NCT04326725HCQInterventional ROLCSNot yet recruitingConvalescent Plasma/HCQ/AZT\
HCQ/AZT80Viral clearance\
IgM titers\
IgG titersColombia\
NCT04332835HCQInterventional ROLSNot yet recruitingQuarantine/no treatment\
HCQ/OTV\
OTV/LPV/RTV\
HCQ/OTV/DRV/RTV\
FAV/LPV/RTV\
HCQ/FAV/DRV/RTV80Viral clearanceThailand\
NCT04303299HCQInterventional SAOLSRecruitingHCQ/LPV/RTV ± OTV50CRP levelJapan jRCTs031190227CQInterventional OLSRecruitingCQ60Symptoms reduction\
Pneumonia preventionGreece\
EudraCT 2020-001345-38CQInterventional ROLCSNot yet recruitingStandard of care\
CQ250Viral clearanceVietnam\
NCT04328493HCQ\
CQInterventional RSBCSNot yet recruitingNatural Honey\
LPV/RTV\
Arbidol\
HCQ\
CQ\
OTV ± AZT1000Viral clearance\
Fever\
Resolution of lung inflammationEgypt\
NCT04323345HCQInterventional RSBCSNot yet recruitingPlacebo\
HCQ/AZT\
HCQ75Clinical statusPakistan\
NCT04328272HCQObservational Randomized TrialNot yet recruitingControl\
HCQ\
AZT\
OTV\
HCQ/AZT\
HCQ/OTV\
AZT/OTV\
HCQ/AZT/OTV500Viral clearancePakistan\
NCT04338698HCQ\
CQInterventional ROLCSNot yet recruitingStandard of care\
HCQ\
CQ950Disease progression\
Admission to ICU or deathNetherlands\
Trial NL8490HCQInterventional RDBPCSRecruitingPlacebo\
HCQ/AZT226Survival\
HospitalizationDenmark\
NCT04322396HCQInterventional\
ROLCSRecruitingControl\
HCQ\
HCQ/LPV/RTV\
Wide range of drugs[b](#tbl6fnb){ref-type="table-fn"}6800Mortality\
Days alive and outside ICUNew Zealand\
NCT02735707HCQInterventional\
RDBPCSNot yet recruitingPlacebo\
HCQ440Viral clearanceAustria\
NCT04336748CQInterventional\
ROLCSNot yet recruitingCQ/OTV\
RTV/DRV/OTV\
LPV/RTV/OTV\
FAV/LPV/RTV\
CQ/RTV/DRV/OTV\
CQ/RTV/DRV/FAV\
Quarantine440Viral clearanceAustria\
NCT04303299CQInterventional ROLCSNot yet recruitingStandard of care\
CQ400Hospitalization or all causes of deathPoland\
NCT04331600[^40][^41][^42][^43][^44][^45]

8. Conclusion {#sec8}
=============

The COVID-19 pandemic has spread out of control and has caused considerable morbidity and mortality in several countries. In this unprecedented situation, clinicians have tried all kinds of treatments in an effort to stem the progression of this disease. One treatment that has received huge attention was the empirical use of anti-malarial CQ/HCQ. While there is no strong and enough scientific and clinical data to support their use, several countries have already included CQ/HCQ in COVID-19 treatment protocols \[[@bib167],[@bib168]\], not only as a treatment option for severely ill patients but also as a prophylactic measure.

In this comprehensive review of the antiviral effects of CQ and HCQ on SARS-CoV-2 as well as other viruses, we show a broad variation in the research outcomes. Both CQ and HCQ demonstrated promising *in vitro* results, however, such data have not yet been translated into meaningful *in vivo* studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary \[[@bib20],[@bib162],[@bib163]\]. Furthermore, at least 7 of the ongoing trials were canceled or stopped and it is not yet clear if this was due to possible adverse effects, ineffectiveness or other reasons.

There are several toxicities associated with these drugs \[[@bib78], [@bib79], [@bib80]\], the one that is foremost concerning is the possibility of QT prolongation and the risk of Torsades de pointes, which is a potentially life-threatening arrhythmia \[[@bib81], [@bib82], [@bib83]\]. Nevertheless, while our literature review showed that this is quite rare, it is not yet evident whether there would be any additive or possible synergistic risk when these drugs are combined with other medications such as AZT \[[@bib83]\]. In fact, it is challenging to base a treatment decision in the absence of a complete research cycle and a clear vision of drug efficacy and safety. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rational the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.
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[^1]: equal contribution.

[^2]: **CQ:** Chloroquine; **CQ-MP**: Chloroquine monophosphate; **CQ-DP**: Chloroquine diphosphate; **AMD**: Amodiaquine; **HCQ**: Hydroxychloroquine; **FQ**: Ferroquine; **HFQ**: Hydroxy ferroquine; **SARS-CoV**: Sever acute respiratory syndrome-coronavirus; **MERS-CoV**: Middle East respiratory syndrome-coronavirus; **SARS-CoV-2**: Sever acute respiratory syndrome-coronavirus 2; **MHV4**: Mouse hepatitis virus Type 4; **F--CoV**: Feline coronavirus; **FIPV**: Feline infectious peritonitis virus; **PHEV:** Porcine hemagglutinating encephalomyelitis virus; **Vero cells**: African green monkey kidney epithelial cells; **Huh7 cells**: Human hepatocyte-derived carcinoma cells; **L132**: human epithelial lung cells; **HRT-18**: Human ileocecal colorectal adenocarcinoma cells; **MΦ**: macrophages; **CRFK cells**: Crandell--Reese feline kidney cells; **fcwf-4 cells**: Felis catuswhole fetus-4 cells; **Neuro-2a**: murine neuroblastoma cells; **EC**~**50**~: 50% Effective concentration; **SI**: Selectivity index defined as the ratio of drug efficacy to cytotoxicity.

[^3]: Tested at different multiplicities of infections (MOIs) of 0.01--0.8.

[^4]: **CQ:** Chloroquine; **HCQ**: Hydroxychloroquine; **FQ**: Ferroquine; **HFQ**: Hydroxy ferroquine; **AMD**: Amodiaquine; **Pre**: pre-treatment; **Post**: post-treatment; **Con**: concurrent; **AQ:** Aminoquinoline; **HIV:** Human immunodeficiency viruses; **IAV**: Influenza A virus; **Flu B**: Influenza B virus **DENV-2:** Dengue virus 2; **ZIKV**: Zika virus; **CHIKV:** Chikungunya virus; **EBOV:** Ebola virus; **SINV**: Sindbis virus; **VSV**: Vesicular stomatitis virus; **PICV**: Pichinde virus; **SLE:** St. Louis encephalitis virus**; POW:** Powassan virus; **NiV:** Nipah virus; **HeV**: Hendra virus; **EBV**: Epstein-Barr virus; **HCV:** Hepatitis C virus**; DHBV**: Duck hepatitis B virus; **JEV:** Japanese encephalitis virus; **MARV:** Marburg virus**; CCHFV:** Crimean-Congo hemorrhagic virus; **HL3Tl**: HeLa derivative cells; **H-9:** Human T lymphocytic cells; **U-937**: Human promonocytic cells; **U-1**: Human promonocytic cells; **ACH-2**: Human T lymphocytic cells; **MΦ**: macrophages; **MT-4 cells**: HTLV-I-transformed T-cell line; **CEM**: Human T lymphoblast cells; **63**: Human macrophage hybridoma; **SP**: T-cell line derived from the pleural fluid of an HIV- 1-infected individual; **63**~**HIV**~: 63 cells infected by HIV; **SPH:** SP cells infected by HIV; **MDCK**: Madin Darby canine kidney; **A549 cells**: Human adenocarcinomic alveolar basal epithelial cells; **BHK/BHK-21 cells**: Syrian golden Syrian golden fibroblast cells; **Vero cells**: African green monkey kidney epithelial cells; **C6/36:** Aedes albopictus cell line; **hBMEC**: Human brain microvascular endothelial cells; **NSCs**: Neural stem cells; **NS**: Neurospheres; **Huh7 cells**: Human hepatocyte-derived carcinoma cells; **HeLa**: Human epithelial cell line; **MDM**: Monocyte-derived macrophages; **HEK 293T**: Human embryonic kidney cells; **MRC-5**: Human normal lung fibroblasts; **MRC-5**: Medical Research Council cell strain 5; **B104:** Rat neuroblastoma cell; **NS-20**: Murine neuroblastoma; **HH514**--**16**: Burkitt lymphoma cell line; **PDH:** Primary duck hepatocytes; **EC**~**50**~: 50% Effective concentration; **SI**: selectivity index defined as the ratio of drug efficacy to cytotoxicity (when no SI value was reported, level of toxicity was indicated if available).

[^5]: Either alone or combined with hydroxyurea (HU1) + didanosine (ddI).

[^6]: In combination with hydroxyurea (HU1) + didanosine (ddI).

[^7]: In combination with hydroxyurea (HU1) + didanosine (ddI) or with hydroxyurea (HU1) + zidovudine (ZDV).

[^8]: Enhanced inhibition against HIV-1 and HIV-2 in combination with HCQ in H9 and MT-4 cells; and against HIV-1 in combination with indinavir (IDV), saquinavir (SQV) or ritonavir (RTV) in MT-4 cells or peripheral blood mononuclear cells (PBMCs).

[^9]: Synergistic inhibitory effect of CQ with IFN-α.

[^10]: A/Mallard/It/43/01 (H7N3).

[^11]: A/Ty/It/220158/02 (H7N3).

[^12]: The haemagglutinins (HAs) of the two avian H7N3 strains differ in two amino acid residues (261 in the HA1 subunit and 161 in HA2 subunit) and display different pH requirements.

[^13]: Viral entry (viral pseudotype assay).

[^14]: Viral replication.

[^15]: Primary cells.

[^16]: Cells stimulated with LPS.

[^17]: Cells stimulated with PMA.

[^18]: Primary non-human primates derived cells.

[^19]: EC~50~ in μg/mL.

[^20]: Suggested enhanced replication and protection of tat from proteolytic degradation with CQ.

[^21]: Suggested inhibition of virus replication based on increased prM protein in progeny virions rather than M protein due to inhibition of proteolytic process.

[^22]: CQ, HCQ and FQ showed no significant activity against parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus, Punta Toro virus, respiratory syncytial virus (RSV), herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), vaccinia virus, vesicular stomatitis virus (VSV), and influenza A virus (H3N2).

[^23]: **CQ:** Chloroquine; **AMD**: Amodiaquine; **SARS-CoV**: Sever acute respiratory syndrome-coronavirus; **FIPV**: Feline infectious peritonitis virus; **IAV**: Influenza A virus: **EBOV:** Ebola virus; **NiV:** Nipah virus; **HeV**: Hendra virus; **LASV:** Lassa fever viruses; **ZIKV:** Zika virus; **CHIKV:** Chikungunya virus; **SFV:** Semliki Forest Virus; **GUPI**: Guinea pig; **NHP**: non-human primate; **i.p:** intraperitoneal; **i.n**: intranasal; **s.c.**: subcutaneous; **i.t**: intratracheal; **i.v**: intravenous; **i.g**: intragastric.

[^24]: Combined with doxycycline (2.5 mg/kg) and azithromycin (50 mg/kg).

[^25]: Either alone or combined with ribavirin.

[^26]: Dose-dependent protection of infected pups when given to mothers prepartum or postpartum (placental and maternal milk transfer).

[^27]: therapeutically but not prophylactically.

[^28]: Disease exacerbation.

[^29]: in both wild type and IFNAR deficient mice. Also, protected infected pups from infection and microcephaly when given to mothers.

[^30]: CQ extended the average lifespan of ZIKV-infected AG129 mice, and suppresses vertical transmission from pregnant infected mice.

[^31]: Disease exacerbation correlating with increased type I IFN response and delayed immune response.

[^32]: **HCQ**: Hydroxychloroquine; **AZT:** Azithromycin; **CQ:** Chloroquine; **ART**: Antiretroviral therapy; **SARS-CoV-2**: Sever acute respiratory syndrome-coronavirus 2; **DENV**: Dengue Virus; **CHIKV**: Chikungunya virus; **HIV**: Human immunodeficiency virus; **SAOLS**: Single arm open labelled study; **RCT:** Randomized clinical trial; **OS:** Observational study; **RDBPCS**: Randomized double blind placebo controlled study; **RDBS**: Randomized double blinded study; **BID**: Twice per day.

[^33]: Small sample size study, 1 death and 3 transferred to ICU among 26 patients treated with HCQ + AZT.

[^34]: 1 patient developed to sever stage.

[^35]: 1 death, 2 transferred to ICU, 1 complained of QT interval prolongation among 11 patients treated with HCQ + AZT.

[^36]: Longer duration of DENV viremia, CQ was associated with a significant reduction in fever clearance time.

[^37]: Temporary improvement in the quality of life.

[^38]: Delayed immune response and more frequent arthralgia in treated group.

[^39]: In one patient.

[^40]: **ROLCS**: Randomized open label controlled study; **RDBS**: Randomized double blind study; **ROLS**: Randomized open label study; **RROLCS**: Retrospective randomized open label controlled study; **RCT**: Randomized clinical trial; **RRSBCS**: Retrospective randomized single blind controlled study; **RSBCS**: Randomized single blind controlled study; **SAOLS**: Single arm open label study; **OLS**: Open label study; **RDBPCS**: Randomized double blind placebo controlled study; **RSBS**: Randomized single blind study; **OLCS**: Open label controlled study; **CSS**: Cross-sectional study; **RPCS**: Randomized placebo controlled study; **RTBCS**: Randomized triple blind controlled study; **CCPS**: Case-control prospective study.

[^41]: **HCQ**: Hydroxychloroquine; **CQ**: Chloroquine; **FAV**: Favipiravir; **LPV**: Lopinavir; **RTV**: Ritonavir; **AZT**: Azithromycin; **Vit C**: Vitamin C; **Vit D**: Vitamin D; **LST**: Losartan; **RDV**: Remdesivir; **IFß-1a**: Interferon β-1a; **NIVO**: Nivolumab; **TCZ**: Tocilizumab; **LEV**: Levamisole; **BUD**: Budesonide; **FORM**: Formoterol; **SOF**: Sofosbuvir; **LDV**: Ledipasvir; **OTV**: Oseltamivir; **ATV**: Atazanavir; **COBI**: Cobicistat; **TDF**: Tenofovir disoproxil fumarate; **FTC**: Emtricitabine; **CIC**: Ciclesonide; **DRV**: Darunavir.

[^42]: **HRCT**: Pulmonary inflammation resolution time, **IMV**: invasive mechanical ventilation; **HCW**: Healthcare workers;; **ARS**: Acute respiratory syndrome; **SpO2/FiO2**: oxygen saturation/fraction of inspired oxygen ratio; **ICU**: Intensive Care Unit; **CRP**: C-reactive protein.

[^43]: Data were obtained from NIH. U.S. National Library of Medicine (<https://www.clinicaltrials.gov/>); the Chinese Clinical Trial Registry (<http://www.chictr.org.cn/>); the European Union Clinical Trials Registry (<https://www.clinicaltrialsregister.eu>); ISRCTN registry (<http://www.isrctn.com/>); Netherlands Trial Registry (<https://www.trialregister.nl/>); Iranian Registry for Clinical Trials (IRCT) (<https://en.irct.ir/>); Japanese Registry for Clinical Trials (JRCT) (<https://jrct.niph.go.jp/>) and the Australian New Zealand Clinical trial Registry (ANZCTR) (<https://www.anzctr.org.au/>).

[^44]: The same study was registered in ISRCTN registry (registration no. ISRCTN50189673) with a total number of 5000 patients.

[^45]: Hydrocortisone, Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Macrolide, OTV, IFβ-1a, and Anakinra.
